(Reuters) -Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences ...

Blackstone Life Sciences agreed to give Merck $700 million to support its development of an investigational cancer drug called sacituzumab tirumotecan in exchange for low-to-mid-single-digit royalties ...

FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug ...

Lab equipment maker Waters Corp raised its annual profit forecast on Tuesday, after beating third-quarter profit estimates on ...

Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an ...

Syndeio Biosciences, a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in CNS disorders, today announced the appointment of Aaron Koenig, M.D., as ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

The Imperial Leather owner’s head of insights talks to Tim Healey about how behavioral understanding, data and technology are ...

Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its third quarter 2025 financial results and recent business activities. Participants may register ...

Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design, today announced the appointment of Bharat Reddy, Ph.D., as its new Chief ...